期刊文献+

uPA与uPAR在肾细胞癌中的表达及其意义 被引量:3

THE EXPRESSION OF uPA AND uPAR IN RENAL CARCINOMA
下载PDF
导出
摘要 ①目的 探讨尿酸氧化酶 (uPA)、尿酸氧化酶受体 (uPAR)在肾细胞癌中的表达特征及其在肾癌恶性生长中的作用。②方法 选取 40例不同分化程度及临床分期的肾细胞癌组织和 1 0例正常肾组织 ,采用Supervi sion法进行免疫组织化学染色 ,检测uPA、uPAR的表达。③结果 uPA、uPAR的表达程度与肾癌细胞分化程度及临床分期有关 ,分化越差、临床分期越晚 ,则表达程度越高。在肿瘤细胞增殖密集区域 ,uPA、uPAR阳性的肿瘤细胞比例较低 ,而在肿瘤细胞生长稀疏、肿瘤血管增殖旺盛的区域 ,阳性细胞比例较高。正常肾组织未见uPA、uPAR的表达。④结论 uPA、uPAR的表达是浸润性生长的肾细胞癌的特征之一 ,其表达程度可作为判断肾癌浸润性的重要参考指标之一。uPA。 Objective\ To study the patterns of expression of urokinase (uPA) and urokinase receptor (uPAR) in human renal carcinoma.\ Methods\ The tissue of 40 cases of different stage and different differentiation renal cell carcinoma and 10 cases of normal kidney were taken for the study. The Supervision immunoperoxidase technique was used for staining. \ Results\ The intensity of the expressions of uPA and uPAR was correlated with the grade of tumour cell and clinical stage. The lower differentiation and later clinical stage, the higher the expressions would be. The expressions of uPA and uPAR were lower in densely proliferated areas and higher in areas of rich vascular proliferation. No expressions of uPA and uPAR were noted in normal renal tissues. Conclusion\ The expression of uPA or uPAR is one of the features of invasive renal carcinoma. The degree of the expression may be used as an important parameter for judgement of its severity. The combined expression of uPA and uPAR may play an important role in the angiogenesis of renal carcinoma.
出处 《齐鲁医学杂志》 2003年第2期121-123,共3页 Medical Journal of Qilu
关键词 肾细胞癌 尿酸氧化酶 尿酸氧化酶受体 免疫组织化学 Supervision法 carcinoma, renal cell urokinase receptors, urokinase immunohistochemistry
  • 相关文献

参考文献9

  • 1郭应禄, 沈绍基..现代泌尿外科诊疗手册[M],1998.
  • 2唐辉滨,朱运松,宋后燕.尿激酶受体的结构和功能及在肿瘤组织中的表达[J].中华医学杂志,1995,75(5):315-317. 被引量:7
  • 3鲍镇美.泌尿系肿瘤[J].中华泌尿外科杂志,1999,20(9):518-520. 被引量:9
  • 4曹祥荣.uPA作用系统的调控与肿瘤[J].国外医学(肿瘤学分册),1994,21(1):9-12. 被引量:3
  • 5Dano K, Andreason PA, Grondahl-Hasen, et al. Plasminogen activitor, tissue degradation and cancer[J]. Adv Cancer Res,1985, 44:139. 被引量:1
  • 6Bouchet C, Spyrators F, Martis PM, et al. Prognostic value of urokinase-type plasminogen activator and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas[J], Br J Cancer, 1994,199:179. 被引量:1
  • 7Del Vecchio S, Stoppeli MP, Carriero MV, et al. Human urokinase receptor concentration in malign and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels[J]. Cancer Res, 1993,53 : 3198. 被引量:1
  • 8Pedersen H, Grondahl-Hansen J, Francis D, et al. Urokinase and plasminogen activator inhibitor type-1 in pulmonary adenocarcinoma[J]. Cancer Res, 1994,54 : 120. 被引量:1
  • 9Grondahl-Hansen J, Christensen I, Rosenquist C,et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis[J]. Cancer Res, 1993,53 ;2513. 被引量:1

二级参考文献1

共引文献15

同被引文献34

  • 1张用书,李秀珍.尿激酶分子系统与肿瘤[J].军事医学科学院院刊,1996,20(3):220-223. 被引量:5
  • 2SJAM G, CORNELIS F M S, MARTINE M H, et al. Prognostic value of the plasminogen activation system in patients with gastric carcinoma[J]. Cancer, 1996, 77:1 035-1 043. 被引量:1
  • 3TETU B, BRISSON J, LAPOINTE H, et al. Prognostic significance of stromelysin- 3, geatinase A, and urokinase expression in breast cancer[J]. Human Pathology, 1998, 29 : 979- 985. 被引量:1
  • 4XING R H, RABBANI S A. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion,growth and metastasis[J]. Int J Cancer, 1996, 67:423 -429. 被引量:1
  • 5SLIUTZ G, EDER H, KOELBL H, et al. Quantification of uPA receptor expression in human breast cancer cell lines by CRT -PCR[J]. Breast Cancer Research and Treatment, 1996, 40:257 - 263. 被引量:1
  • 6G RONDAHL- HANSEN J, HILSENBECK S G, CHRISENSEN I J, et al. Prognostic significance of PAI- 1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients[J ].Breast Cancer Research and Treatment, 1997, 43:153 - 163. 被引量:1
  • 7CHO J Y, CHUNG H C, NOH S H, et al. High level of urokinase- type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer, 1997. 78:878 - 883. 被引量:1
  • 8MAEDA K, CHUNG Y S, SAWADA T, et al. Combined evaluation of urokinase- type plasminogen activator and plasminogen activator inhibitor - 2 expression in gastric carcinoma[J]. IntJ Oncology, 1996, 8: 499-503. 被引量:1
  • 9ABE J, URANO T, KONNO H, et al. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size[J]. Cancer, 1999, 80:2 602- 2 611. 被引量:1
  • 10NEKARDAH, SCHLEGELP, SCHMITTM, etal. Strong prognostic impact of tumor associated urokinase- type plasminogen activator in completely resected adenocarcinoma of the esophagus[J]. Clinical Cancer Research, 1998, 4:1 755-1 763. 被引量:1

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部